BCHE Down (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with BCHE Down.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with BCHE Down.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with BCHE Down.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with BCHE Down.

Results found

Linked to

 

Label

Description

 

Gene

ENSG00000151465 - cell division cycle 123

Gene

ENSG00000121578 - beta-1,4-galactosyltransferase 4

Gene

ENSG00000118217 - activating transcription factor 6

Gene

ENSG00000143222 - ubiquitin-fold modifier conjugating enzyme 1

Gene

ENSG00000132912 - dynactin subunit 4

Gene

ENSG00000166228 - pterin-4 alpha-carbinolamine dehydratase 1

Gene

ENSG00000085760 - mitochondrial translational initiation factor 2

Gene

ENSG00000151846 - poly(A) binding protein cytoplasmic 3

  • Gene

    ENSG00000151465 - cell division cycle 123


  • Gene

    ENSG00000121578 - beta-1,4-galactosyltransferase 4


  • Gene

    ENSG00000118217 - activating transcription factor 6


  • Gene

    ENSG00000143222 - ubiquitin-fold modifier conjugating enzyme 1


  • Gene

    ENSG00000132912 - dynactin subunit 4


  • Gene

    ENSG00000166228 - pterin-4 alpha-carbinolamine dehydratase 1


  • Gene

    ENSG00000085760 - mitochondrial translational initiation factor 2


  • Gene

    ENSG00000151846 - poly(A) binding protein cytoplasmic 3

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.